Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, April 5, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Geulah Livshits Maintained (ACHL) at Strong Buy with Decreased Target to $6 on, Apr 5th, 2024
Geulah Livshits of Chardan Capital, Maintained "Achilles Therapeutics plc" (ACHL) at Strong Buy with Decreased Target from $11 to $6 on, Apr 5th, 2024.
Geulah has made no other calls on ACHL in the last 4 months.
There is 1 other peer that has a rating on ACHL. Out of the 1 peers that are also analyzing ACHL, 0 agree with Geulah's Rating of Hold.
This is the rating of the analyst that currently disagrees with Geulah
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Sell and Decreased Target to $0.5 on, Thursday, December 14th, 2023
